Treatment of Indolent Systemic Mastocytosis With PA101

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

June 30, 2016

Conditions
MastocytosisSystemic MastocytosisIndolent Systemic Mastocytosis
Interventions
DRUG

PA101

40 mg PA101 administered via inhalation three times daily for 6 weeks

DRUG

Placebo

matching placebo administered via inhalation three times daily for 6 weeks

Trial Locations (8)

Unknown

Hopital Necker - Enfants Malades, Paris

Charité - Universitätsmedizin Berlin, Berlin

Klinikum Darmstadt, Darmstadt

University Medical Center Mainz, Mainz

Technical University München, Munich

University of Salerno, Salerno

University Medical Center of Groningen, Groningen

Hospital Universitario de Fuenlabrada, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Patara Pharma

INDUSTRY